Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duration of Concentrated vs Standard Jeuveau for Glabellar Lines
NCT05129319Phase 1Completed
- Sponsor
- Clinical Testing of Beverly Hills
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of botulinum toxin type A in glabellar lines (2 arms), sponsored by Clinical Testing of Beverly Hills. Primary endpoint: Response Duration at 270 days. Started Dec 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05129319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129319.